To analyze the effect of loss of exclusivity of data on the cost of treatment of peripheral neuropathic pain (PNP) with pregabalin or gabapentin in routine clinical practice. A retrospective observational study, with electronic medical records for patients enrolled at primary care centers managed by the health care provider Badalona Serveis Assistencials, who initiated treatment of PNP with pregabalin or gabapentin. The analysis used drugs and resources prices for year 2015. The 1163 electronic medical records (pregabalin; N = 764, gabapentin; N = 399) for patients (62.2% women) with a mean (standard deviation) age of 59.2 (14.7) years were analyzed.
In some patients, PNP is difficult to treat. [1] [2] [3] Neuromodulators such as pregabalin and gabapentin are considered to be treatments of choice for PNP. 1, 3, [8] [9] [10] Both drugs seem to have a positive impact on the set of symptoms accompanying PNP and have similar efficacy and tolerability profiles. [8] [9] [10] [11] [12] The major difference between them lies in their pharmacokinetics, because pregabalin has a better pharmacokinetic profile, with linear absorption regardless of dose and receptor affinity 6 times greater than that of gabapentin. These aspects may explain why pregabalin is clinically more effective at a lower dose. [13] [14] [15] In addition, both medicines have now lost data exclusivity in the treatment of PNP, and their public and funding prices has therefore been substantially reduced.
PNP has a high impact, particularly on sufferers, and also on the society in general as well, becoming to be considered a public health problem. 1, 3 Patients experience a worsening of their state of health and a greater degree of disability, and they often develop mood disorders associated with anxiety, depression, and sleep disorders. [16] [17] [18] These events translate to a loss of quality of life that affects their family and working lives. 1, 3 As a consequence, PNP is associated with high costs both direct health care (treatment, visits, etc.) and indirect (work performance). 18, 19 On the other hand, available evidence comparing pregabalin and gabapentin for resource use and cost is limited. [19] [20] [21] [22] Moreover, new data are required adapted to the changing scenarios 
| METHODS AND PATIENTS

| Study design and population
This study was conducted using the database from a previous study, 21 with a retrospective observational design, and based on the review of electronic medical records (EMRs) (electronic databases with dissociated data) for patients followed up on an outpatient or inpatient basis, from 6 primary care centers (managed by Badalona Serveis Assistencials) and their reference hospital (Hospital Municipal de Badalona). The population assigned to those centers was mostly urban, of medium-low socioeconomic standing and predominately workingclass. The patients enrolled in the study had sought care with a diagnosis of PNP according to the ICPC-2 classification (described below) of the area, as well as patients treated simultaneously with both medicines during the study period, were excluded from the study.
| Treatments administered
Information was obtained on the dose and duration of the main treatments studied-gabapentin and pregabalin-based on the information provided by the Catalan Health Service (CatSalut). Data were gathered on the number and format of the prescriptions received by the patients starting from the first prescription, within the abovementioned study period and for the 24 months following the start of treatment, and all EMRs that met selection criteria were extracted. Also for the 24-month follow-up period, information was obtained on the pharmacological prescriptions for specific and concomitant medicines for PNP 29 All costs were determined in the 24 months following the start of treatment with gabapentin or pregabalin. This study did not consider computing direct non-health care costs, ie, costs considered to be "out-of-pocket" expenses or paid by the patient/family, as they were not recorded in the database.
| Confidentiality of information and quality control
The 
| Statistical analysis
The sample size was not predetermined a priori, given that the study 
| RESULTS
From an initial selection of 86 206 patients more than 18 years of age assigned to the centers, 1160 patients were recruited who met the Abbbreviation: PSP, public selling price.
Source of health care resources: analytical accounting (year 2015).
Values are expressed in euros. Table 2 shows the baseline characteristics of the series studied and distribution of the different types of PNP by study group. Age and sex showed numerical differences that did not achieve statistical significance: a mean age of 59. (therapeutic range 900 to 1800 mg/day).
In follow-up (2 years), the patients in the pregabalin group used fewer health care resources in medical visits in outpatient care (10.8 Table 4 . Table 5 shows the gross and corrected costs associated with PNP according to study group. The total cost for the patients enrolled in the study amounted to €3.3 million, 51.9% of which was for direct health care costs, and 48.1% of which was for non-health care costs (productivity losses), with a total average per unit of €2,711.3. Of the total costs, 38.5% were incurred in primary care, 13.4% were incurred in specialized care, and, of the latter, 15.4%
were incurred in drug prescription. By group, the total costs (health care and non-health care) for the patients on treatment with pregabalin were lower in comparison with gabapentin (€2,427.8 versus €3,254.1; P = 0.001). These differences were maintained after adjusting for covariates ( Table 5 (181.9), P < 0.001, although the cost of concomitant analgesic medication was significantly lower; €176.5 (271.8) vs €306.7 (529.2), P < 0.001, yielding that the total cost in analgesic medication was significantly lower in the pregabalin group; €391 vs €464, P < 0.05
( Figure 1 ). Most cost components were lower with pregabalin, except for those observed in specialized care. Table 6 lists the distribution of the main cost components according to sex, age, and main diagnoses by study group. It should be noted that differences in average costs per patient observed in the whole sample were maintained in all subgroups, such that the patients on treatment with pregabalin were associated with lower both total and health care costs, except for subgroups of painful diabetic neuropathy and painful mononeuropathies whose differences did not reach statistical significance because of the small sample size of these subgroups (Table 6 ).
| DISCUSSION
This study analyzed the effect of loss of data exclusivity for pregabalin and gabapentin on the cost of PNP with these medicines, given that this is important information for decision-making in health under routine medical practice conditions in the Spanish health care setting, and owing to the extensive use made of these drugs. There have been very few economic studies conducted in Spain or other countries comparing the cost of treatment of PNP with pregabalin and gabapentin, and we are not aware of any with our study's objective. Before loss of data exclusivity, the total cost of PNP per patient was around €728 lower in those treated with pregabalin than in those receiving gabapentin during the 2 years of follow-up of the patients, €162 of which was for the health care cost component. 21 This difference (statistically significant, P = 0.003) was explained by lower use of health care resources (mainly medical visits and concomitant analgesic Figure 1) . 21 Although loss of data exclusivity has caused a considerable reduction of funded and public prices for both pregabalin and gabapentin since then, there is still a relevant gap in their cost when used to treat PNP in routine medical practice in Spain. However, because of the reduction observed in the price of concomitant analgesic medication between the 2 analyses, the combined cost for all analgesic medication, which before was practically equal (€572 with pregabalin vs €575 with gabapentin), has been considerably reduced at present, especially in the pregabalin group;
€391 vs €464, P < 0.05 (Figure 1) . Nonetheless, and despite the aforementioned reduction in the cost of acquisition of analgesic medication, owing a significant reduction in the primary care component of costs, such reduction was partially offset by the increase in the cost of the other treatment components. As a consequence, the total costs per patient varied only within a range of €40 to€100 and there remained a substantial saving of €788 per patient for pregabalin in comparison with gabapentin following loss of data exclusivity (€231 in the health care component funded by the Spanish National Health System).
These results were consistent when analyzed separately by sex, age group, and different types of aetiology causing PNP, except for painful mononeuropathy (postherpetic and trigeminal neuralgia), in which the differences did not reach statistical significance as a consequence of the small number of patients.
This study determined disease cost based on the longitudinal follow-up of patients cared for at different health care levels in a routine clinical practice setting and from a population perspective. It is one of the series with the highest number of subjects studied, which should be interpreted as a study strength. [31] [32] [33] [34] [35] [36] However, it should be noted that without appropriate standardization of patient characteristics, as well as in the number and extent of the variables studied, the results There are many studies in the scientific literature on the impact of patent protection and loss of data exclusivity on the prices of medicines and their potential impact on pharmaceutical spending.
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However, we did not find any studies similar to ours in the Spanish scientific literature analyzing the effect of the reduction in the cost of acquisition of medicines due to loss of data exclusivity on disease cost under real-life conditions such as those conducted in other settings with other types of drug. [44] [45] [46] Nonetheless, the information that this study provides may be important for health care decision-makers, particularly those interested in the area of pain. Our study, as 
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